High materiality8/10
Truist Reiterates Buy Rating on Viridian Therapeutic (VRDN) Following FDA approval
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Truist Financial reiterates Buy on VRDN after FDA approval. Target 35; current price 18.45; price change since signal 0.45.
- Target $35; current $18.45; +$0.45 since signal.
Key facts
- 01
Target: $35
- 02
Posted price: $18.45
- 03
Analyst firm: Truist Financial
- 04
Analyst: Greg Renza
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.